Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00359307 · ClinicalTrials.gov registry record
Genetic Factors in Atherosclerosis
A clinical trial of Atherosclerosis, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 1,888
- Enrollment target
- 1
- Study location
NCT00359307 is a study of Atherosclerosis that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 1,888 participants, above the 1,038-participant average among 69 other Atherosclerosis trials with a reported enrollment target (82% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00359307, a study of Atherosclerosis, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 1,888 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to identify genes associated with certain risk factors for atherosclerosis (hardening of the arteries) and its consequences, such as development of coronary artery disease, heart attack, other blood vessel disease and stroke. People enrolled in the Framingham Heart Study in Framingham, Massachusetts, are eligible to participate in this study. They will undergo a medical history, including review of their medical records and a family history; evaluation of memory and mood; breathing test and electrocardiogram (EKG); blood and urine tests, including blood sample collection for DNA (genetic) testing; evaluation of gait (walking), balance and hand grip strength; and hearing test. They will also fill out questionnaires on their eating habits and general health. Any patients who may suffer a stroke during the study will be examined during their hospitalization and at 3, 6, 12, and 24 months after the stroke. This examination includes a neurological evaluation, assessment of ability to perform daily living tasks and, possibly, magnetic resonance imaging (MRI) of the brain, a test that uses a strong magnetic field and radio waves to produce pictures of the brain.
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,888 participants |
| Start Date | 2000-06-08 |
| Est. Completion | 2013-03-21 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00359307
The ClinicalTrials.gov registry entry for NCT00359307 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,888 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,038-participant average among 69 other Atherosclerosis trials with a reported enrollment target (82% higher). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atherosclerosis appearing as the primary indexed condition, and to 0 interventions.
NCT00359307 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00359307 about?
NCT00359307 is a clinical study titled "Genetic Factors in Atherosclerosis". The purpose of this study is to identify genes associated with certain risk factors for atherosclerosis (hardening of the arteries) and its consequences, such as development of coronary artery disease, heart attack, other blood vessel disease and stroke. People enrolled in the Framingham Heart Stud...
What is the current status of trial NCT00359307?
This trial is currently completed. The enrollment target is 1,888 participants. The study started on 2000-06-08. Estimated completion is 2013-03-21.
What conditions does trial NCT00359307 study?
This clinical trial studies the following conditions: Atherosclerosis.
Who is sponsoring clinical trial NCT00359307?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00359307 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atherosclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
RECRUITING · Phase 4
-
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
RECRUITING · NA
-
PET/CT* vs. Cardiac CT for Detecting Coronary Atherosclerotic Disease [*PET: Positron Emission Tomography; CT: Computed Tomography]
RECRUITING · NA
-
Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
RECRUITING
-
New Heart Imaging Techniques to Evaluate Possible Heart Disease
RECRUITING · NA
-
Natural History of Uncommon Dyslipidemias, Rare Lipid Disorders and Unusual Atherosclerotic Conditions
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.